Relationship between COX-2 specific inhibitors and hypertension

Hypertension
Daniel H SolomonJerry Avorn

Abstract

There is controversy whether cyclooxygenase-2 (COX-2) specific inhibitors are associated with elevations in blood pressure requiring treatment in typical clinical practice. We examined the risk of new onset hypertension in a retrospective case-control study involving 17 844 subjects aged > or =65 years from 2 US states. Multivariable logistic models were examined to assess the relative risk of new onset hypertension requiring treatment in patients who used celecoxib or rofecoxib compared with patients taking either the other COX-2 specific inhibitor, a nonspecific NSAID, or no NSAID. During the 1999 to 2000 study period, 3915 patients were diagnosed and began treatment for hypertension; 4 controls were selected for every case. In no model was celecoxib significantly associated with the development of hypertension. Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1.6; 95% confidence interval [CI], 1.2 to 2.1), taking a nonspecific NSAID (OR 1.4; 95% CI, 1.1 to 1.9), or taking no NSAID (OR 1.6; 95% CI, 1.3 to 2.0). There were no clear dosage or duration effects. In patients with a history of chronic renal disease, liver disease, or c...Continue Reading

References

Aug 15, 1994·Annals of Internal Medicine·A G JohnsonR O Day
Sep 14, 1994·JAMA : the Journal of the American Medical Association·J H GurwitzH Mogun
May 11, 1999·The American Journal of Gastroenterology·P L MosesS D Lidofsky
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Mar 29, 2001·American Journal of Nephrology·D C BraterB J Gertz
Aug 11, 2001·The New England Journal of Medicine·G A FitzGerald, C Patrono
Feb 15, 2002·The New England Journal of Medicine·Judy A StaffaLanh Green
Oct 26, 2002·The American Journal of Cardiology·Andrew WheltonUNKNOWN SUCCESS-VII Investigators
Jan 29, 2003·Circulation·Rémy ChenevardFrank Ruschitzka

❮ Previous
Next ❯

Citations

Apr 6, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Irmgard Tegeder, Gerd Geisslinger
Sep 1, 2005·European Journal of Clinical Pharmacology·G DurrieuUNKNOWN French networks of Pharmacovigilance centers
Jun 3, 2006·Clinical Rheumatology·Robert Raffa
Feb 3, 2005·Current Hypertension Reports·Matthias HermannFrank T Ruschitzka
Mar 17, 2007·Current Hypertension Reports·Frank Ruschitzka
Jan 5, 2008·Current Pain and Headache Reports·Carla R ScanzelloAllan Gibofsky
Mar 23, 2005·Current Opinion in Pharmacology·Dairong WangGarret A Fitzgerald
Jun 14, 2005·Trends in Endocrinology and Metabolism : TEM·Bukhtiar H Shah
Nov 28, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Liffert VogtGerjan Navis
Jun 21, 2006·Journal of Cardiovascular Pharmacology·Jan SteffelFelix C Tanner
Jun 21, 2006·Journal of Cardiovascular Pharmacology·Henry KrumSteven Haas
Oct 21, 2006·Current Opinion in Rheumatology·Stephen M RothLuigi Ferrucci
Jun 3, 2011·Clinical and Experimental Pharmacology & Physiology·Megan M WennerWilliam B Farquhar
Apr 2, 2008·Circulation·Scott D SolomonUNKNOWN Cross Trial Safety Assessment Group
Sep 17, 2004·The Journal of Clinical Investigation·Helene Francois, Thomas M Coffman
Jan 6, 2006·The Journal of Clinical Investigation·Tilo GrosserGarret A FitzGerald
Aug 1, 2010·Therapeutic Advances in Musculoskeletal Disease·Paolo VerdecchiaGianpaolo Reboldi
Nov 1, 2005·Future Cardiology·Danny Liew, Henry Krum
Aug 8, 2013·Clinical and Experimental Nephrology·Hisazumi ArakiTakashi Uzu
May 7, 2008·Current Rheumatology Reports·Carla R ScanzelloAllan Gibofsky
Feb 18, 2011·Canadian Journal of Physiology and Pharmacology·Vivian BoshraManar A Nader
Oct 18, 2011·Journal of Hypertension·Gian P RossiAchille C Pessina
Oct 21, 2006·Current Opinion in Cardiology·Scott D Solomon
Oct 26, 2012·Critical Reviews in Clinical Laboratory Sciences·Matthew D Linden, Huyen A Tran
Feb 24, 2016·Critical Reviews in Oncology/hematology·Ana BobanCedric Hermans
Jun 7, 2005·Expert Opinion on Drug Safety·Michel Burnier
Mar 16, 2013·Clinical and Experimental Hypertension : CHE·Preeta Kaur ChughUma Tekur
May 12, 2009·Annals of Medicine·Richard H HuntCarmelo Scarpignato
Aug 2, 2011·Prostaglandins & Other Lipid Mediators·Christina E Swan, Richard M Breyer
Mar 27, 2010·The Journal of Pain : Official Journal of the American Pain Society·Robert B RaffaRonald J Tallarida
May 6, 2009·The American Journal of Medicine·William B White
Oct 22, 2008·Cardiology Clinics·Orly Vardeny, Scott D Solomon
Dec 6, 2007·La Presse médicale·Jean-Pierre ValatFrançois Héloire
Jan 8, 2008·Seminars in Arthritis and Rheumatism·Loren LaineMarc Hochberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the Royal Society of Medicine
Brent CaldwellRichard Beasley
JAMA : the Journal of the American Medical Association
D MukherjeeEric J Topol
The New England Journal of Medicine
Robert S BresalierAdenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators
© 2022 Meta ULC. All rights reserved